9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Settlement Agreement with UPenn and Sarepta for Patent Litigation
Strengthens Board of Directors with Appointment of Greg Ciongoli
Announces Regulatory Update on RGX-121 for MPS II
Reports Second Quarter 2026 Financial Results and Operational Highlights
Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; to Receive $100 Million Milestone
Material disclosure
Reports First Quarter 2026 Financial Results and Operational Highlights
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
SC TO-I
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Amended Tender Offer Statement by Issuer
Correspondence
Submission Upload